not tagged
daiichi sankyo
['sclc', 'nsclc', 'daiichi']
 2022 updates: presented phase i results of patitumab deruxtecan in #egfr activating mutated squamous/non-squamous #nsclc with disease progression during or after systemic treatment for locally advanced/metastatic disease. learn more: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry